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Epidemiology and Social
Objective: To describe effects of HAART on high-risk human papillomavirus (HPV) antibody response in
HIV-positive MSM and the meaning of this response for subsequent HPV-related cancer risk.
Design: Prospective seroepidemiological study of 281 HIV-positive MSM initiating HAART between 1995 and
2004 in the Swiss HIV Cohort Study.
Methods: For each individual, two serum samples, one at HAART initiation (pre-HAART) and another 24
months later (post-HAART), were tested for L1 antibodies to HPV6, 11, 16, 18, 31, 33, 35, 45, 52 and 58, as well
as HPV16-E6 antibodies, using a multiplex serology assay. Identification of HPV-related cancer included data
linkage with Swiss cancer registries.
Results: Pre-HAART, 45.2% were seropositive for any high-risk HPV-L1 and 32.4% for HPV16-L1. Sexual
intercourse during the last 6 months was the only evaluated factor associated with L1 seropositivity pre-HAART.
Seropositivity increased post-HAART to 60.5% for any high-risk HPV-L1 [prevalence ratio versus pre-HAART =
1.34, 95% confidence interval (CI) 1.14–1.57] and 48.0% for HPV16-L1 (prevalence ratio versus pre-HAART =
1.48, 95% CI 1.20–1.83), and seroconversion was significantly associated with both lower CD4  cell count and
CD4 /CD8  ratio (P < 0.01). Only one individual was HPV16-E6-seropositive pre-HAART, but two more
seroconverted post-HAART. Anal cancer incidence among the three HPV16-E6-positives post-HAART was
significantly increased compared with HPV16-E6-negatives (incidence rate ratio = 63.1, 95% CI 1.1–1211).
Conclusion: HAART-related immune reconstitution increases HPV-specific antibody responses, which may
discriminate future anal cancer risk in this high-risk population.
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